Case report

Recurrent pancreatic cancer patient treated by chemotherapy and focused ultrasound surgery. A case report

Dobromir Dimitrov¹,², Nadya Stanislavova², Tsanko Yotsov¹, Kun Zhou³

¹Department of Surgical Propaedeutics, Medical University-Pleven, Bulgaria, ²HIFU Center, St. Marina Hospital, Medical University-Pleven, Bulgaria, ³Clinical Center for Tumor Therapy of the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

Introduction

Radical surgery for pancreatic cancer has median survival for all stages of 12.6 months. It is however possible in only 20% of the patients [1,2]. Despite the R0 resection, most patients will experience a local recurrence or progression of disease with hepatic metastases or peritoneal carcinomatosis [3]. Recurrences remain a challenge for treatment as operative treatment and chemoradiation have limited efficiency and the advancement of stage of the disease. The pessimistic attitude of clinicians towards recurrent pancreatic cancer is very common, which leads to untreated recurrence or palliation of the patients [4].

The present report of a patient with recurrent pancreatic cancer after radical surgery treated successfully with chemotherapy and local ablation with focused ultrasound surgery (FUS).

Case report

In 2014 a 61-year old patient underwent a successful Whipple’s procedure for adenocarcinoma of the head of the pancreas. The stage of the disease was T2N0(10), I stage. Seven months after the operation because of abdominal and lower back pain, a contrast enhanced computer tomography (CT) was performed. The CT evidenced a tumor in the body of the pancreas around metal clips suspicious of local recurrence. A positron emission tomography CT (PET-CT) was performed for confirmation of the diagnosis. It shows a tumor formation at the...
site of operation with dimensions 24/20/22 mm, volume 5.5 ml and max SUV 7.4 (fig 1). The tumor mass was in contact with the inferior cava vein, superior mesenteric artery and aorta. The case was presented for discussion at the High Intensity Focused Ultrasound (HIFU) center in University Hospital “St. Marina”, MU-Pleven. At this point the patient reported pain measured by the visual analog scale (VAS) at 8 out of 10 points, which was treated with 50 mg tramadol two times a day. The comorbidity of the patient was diabetes mellitus and hypothyroidism. The European Organisation for Research and Treatment of Cancer (EORTC) instrument Quality of Life Questionnaire cancer 30 was used to evaluate the patient before and after ablation. The baseline answers of the patient showed poor global health status (GHS) with 0 points and moderate pancreatic pain (50 points) treated with drugs. FUS with HIFU and adjuvant treatment with Gemcitabine (1,600 mg/m² i.v. weekly) were proposed to the patient.

After signing an informed consent form, the FUS treatment was performed. The patient was prepared for general anesthesia beforehand with no out of norm tests and consultation examinations. The patient was positioned prone on the HIFU table model JC Chongqing Haifu Medical Technology Co. Ltd., China. Between the anterior abdominal wall of the patient and the HIFU transducer was placed a special balloon used to compress the viscera, shorten the acoustic pathway and cool the skin during procedure. The FUS was performed with duration 105 minutes and mean dose per 1ml of tumor mass 12307.30 J/ml. First hyperechogenic changes in real time in the pancreas appeared at 337 seconds as an ultrasound sign of coagulative necrosis (fig 2). The patient was discharged after 5 days in a good general condition, without complications. Adjuvant chemotherapy was performed with 10 cycles of Gemcitabine after FUS. The control CT showed wide hypodense zone, with no sign of enhanced contrast area (fig 3). At the same time VAS was reduced to 3 out of 10 and the patient ceased to use Tramadol. Using the EORTC standards GHS reached 67 points and the pancreatic pain was 0 according to the patient. Twelve months after FUS, PET-CT showed no progression of the disease (fig 4). The registered survival of the patient after FUS was 24 months and 32 months after diagnosis.

**Discussions**

FUS using a HIFU as a non-invasive procedure that can be used in treatment of benign or malign tumors and can be guided with no need of puncture, needle or incision of the skin surface. The method uses HIFU waves, focused on a lesion with the help of special equipment with build in imaging device – MRI or ultrasound, and calculation devices for precise focus of the ultrasound waves. When the ultrasound waves reach the target locus they superpose and the result wave has higher energy than the summer energy of the separate waves. It is absolutely non-invasive for the surround tissues and the skin. The result wave causes rapid increase in the temperature of the tumor mass and cavitation. There have been trials with European and Asian patients that show better therapeutic results in advanced pancreatic cancer [5,6].

Median time to early recurrence is 3.7 months and median overall survival with chemotherapy is 9.3 months.
The recurrence in our case was diagnosed 7 months after Whipple resection. Resection of recurrent pancreatic cancer is uncommon and performed only in selected cases [3,4]. In the presented case the pancreatic surgeons did not offer a resection of the recurrence. According to the MDT FUS was performed in one go with a registered very good result, no complications and necrosis confirmed by CT. In the literature there are few cases successfully treated by HIFU and chemotherapy for locally advanced pancreatic cancer and no recurrent cases [8,9]. Wilkowski et al. reported median overall survival in patients with recurrence after pancreatic resection treated with chemoradiation of 17.5 months and median survival after initial diagnosis 27.2 months [10].

The presented case is unique according to the literature as a local recurrence after radical surgery for pancreatic cancer, successfully managed by local FUS ablation and adjuvant chemotherapy.

References: